Use of Low-dose Sulodexide in IgA Nephropathy Patients on Renin-angiotensin System Blockades

Overview

Journal Kidney Res Clin Pract

Specialty Nephrology

Date 2016 Feb 20

PMID 26894022

Authors

Byeong Yun Yang

Hee Seon Lee

Sang Heon Song

Ihm Soo Kwak

Soo Bong Lee

Dong Won Lee

Eun Young Seong

Affiliations

Soon will be listed here.

Abstract

Background: Despite using renin-angiotensin system (RAS) blockades, some of the patients with immunoglobulin A (IgA) nephropathy often had persistent proteinuria of more than 500 mg/d. They need to be managed further by alternative methods to halt the progression of the disease; these methods could also be applied safely over a long period of time. In this context, sulodexide has been studied for the management of diabetic nephropathy.

Methods: A retrospective review was carried out involving 20 patients with IgA nephropathy who had been taking sulodexide (50 mg daily) as an add-on therapy together with an optimal dose of RAS blockades during 2008-2009. We evaluated the proteinuria reduction rates and renal function changes.

Results: During 11.1±72.7 months of follow-up duration, urinary protein-to-creatinine ratio (UPCR) decreased for 1.57±0.6 to 1.17±0.7 g/g (P=0.032). Twenty-five percent of the patients showed a greater than 50% reduction of UPCR, and 40% had a UPCR of less than 1.0 g/g at their final observations. The analysis of the factors contributing to the effect found that a higher pretreatment UPCR showed a significant correlation with the UPCR decrease (r=0.45, P=0.047). Neither the adverse effects nor the renal function impairments were documented during the management.

Conclusion: Low-dose sulodexide has an additional modest antiproteinuric effect on IgA nephropathy undergoing RAS blockade therapy.

References

Alamartine E, Sabatier J, Guerin C, Berliet J, Berthoux F . Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analyses. Am J Kidney Dis. 1991; 18(1):12-9. DOI: 10.1016/s0272-6386(12)80284-8. View

Szeto C, Chow K, Kwan B, Chung K, Leung C, Kam-Tao Li P . Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial. Am J Kidney Dis. 2008; 51(5):724-31. DOI: 10.1053/j.ajkd.2007.12.038. View

Praga M, Gutierrez E, Gonzalez E, Morales E, Hernandez E . Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol. 2003; 14(6):1578-83. DOI: 10.1097/01.asn.0000068460.37369.dc. View

Coppo R, Peruzzi L, Amore A, Piccoli A, Cochat P, Stone R . IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol. 2007; 18(6):1880-8. DOI: 10.1681/ASN.2006040347. View

Gambaro G, Kinalska I, Oksa A, Pontuch P, Hertlova M, Olsovsky J . Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol. 2002; 13(6):1615-25. DOI: 10.1097/01.asn.0000014254.87188.e5. View

Bang K, Chin H, Chae D, Joo K, Kim Y, Kim S . Anti-proteinuric effect of sulodexide in immunoglobulin a nephropathy. Yonsei Med J. 2011; 52(4):588-94. PMC: 3104455. DOI: 10.3349/ymj.2011.52.4.588. View

Sharma S, Spencer T, Gokden N . The significance of foot process effacement in immunoglobulin a nephropathy: clinicopathologic study of 161 cases with light, immunofluorescence and electron microscopic studies. Ultrastruct Pathol. 2010; 34(5):269-72. DOI: 10.3109/01913123.2010.487971. View

Liu L, Lv J, Shi S, Chen Y, Zhang H, Wang H . Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis. 2011; 59(1):67-74. DOI: 10.1053/j.ajkd.2011.09.014. View

Solini A, Vergnani L, Ricci F, Crepaldi G . Glycosaminoglycans delay the progression of nephropathy in NIDDM. Diabetes Care. 1997; 20(5):819-23. DOI: 10.2337/diacare.20.5.819. View

10.

Choi S, Lee D, Jeong K, Moon J, Lee S, Lee T . Prognostic relevance of clinical and histological features in IgA nephropathy treated with steroid and angiotensin receptor blockers. Clin Nephrol. 2009; 72(5):353-9. DOI: 10.5414/cnp72353. View

11.

Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi G, Altieri P . Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2003; 15(1):157-63. DOI: 10.1097/01.asn.0000103869.08096.4f. View

12.

Cheng J, Zhang X, Zhang W, He Q, Tao X, Chen J . Efficacy and safety of glucocorticoids therapy for IgA nephropathy: a meta-analysis of randomized controlled trials. Am J Nephrol. 2009; 30(4):315-22. DOI: 10.1159/000226129. View

13.

Sorrenti G, Grimaldi M, Canova N, Palazzini E, Melchionda N . Glycosaminoglycans as a possible tool for micro- and macroalbuminuria in diabetic patients. A pilot study. J Int Med Res. 1997; 25(2):81-6. DOI: 10.1177/030006059702500204. View

14.

Burney B, Kalaitzidis R, Bakris G . Novel therapies of diabetic nephropathy. Curr Opin Nephrol Hypertens. 2009; 18(2):107-11. DOI: 10.1097/MNH.0b013e3283249c51. View

15.

Maxhimer J, Somenek M, Rao G, Pesce C, Baldwin Jr D, Gattuso P . Heparanase-1 gene expression and regulation by high glucose in renal epithelial cells: a potential role in the pathogenesis of proteinuria in diabetic patients. Diabetes. 2005; 54(7):2172-8. DOI: 10.2337/diabetes.54.7.2172. View

16.

Manno C, Torres D, Rossini M, Pesce F, Schena F . Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant. 2009; 24(12):3694-701. DOI: 10.1093/ndt/gfp356. View

17.

Lai K, Lai F, Ho C, Chan K . Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial. Clin Nephrol. 1986; 26(4):174-80. View

18.

Achour A, Kacem M, Dibej K, Skhiri H, Bouraoui S, May M . One year course of oral sulodexide in the management of diabetic nephropathy. J Nephrol. 2005; 18(5):568-74. View

19.

Lv J, Zhang H, Chen Y, Li G, Jiang L, Singh A . Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis. 2008; 53(1):26-32. DOI: 10.1053/j.ajkd.2008.07.029. View

20.

Tomino Y, Sakai H . Clinical guidelines for immunoglobulin A (IgA) nephropathy in Japan, second version. Clin Exp Nephrol. 2003; 7(2):93-7. DOI: 10.1007/s10157-003-0232-4. View